Where Will Eli Lilly Stock Be in 10 Years?

Eli Lilly (NYSE: LLY) wasn't the archetypal to marketplace with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for value loss) drugs person proven much effectual than competing products. That's moved Eli Lilly to the caput of the pack, but investors whitethorn beryllium a spot excessively excited astir the company's prospects. In 10 years, the communicative astir this banal is apt to beryllium precise different.

Sales of Mounjaro roseate 99% successful 2025. Zepbound's income roseate an adjacent much awesome 175%. Eli Lilly is the wide person successful the GLP-1 cause abstraction with these highly palmy drugs.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

That's bully news, but investors are good alert of the company's success. The stock's price-to-earnings ratio is simply a precise precocious 44. By comparison, stocks successful the S&P 500 person an mean P/E of 28, and the mean pharmaceutical stock's P/E is conscionable nether 23.

Investors excited astir GLP-1 drugs person priced a batch of bully quality into Eli Lilly's stock. Notably, Mounjaro and Zepbound presently relationship for 56% of the company's gross and astir of its growth. Buying Eli Lilly close present is simply a stake that the company's GLP-1 occurrence continues.

The occupation with buying Eli Lilly astatine its existent valuation is that the pharmaceutical assemblage has a wide past to look backmost on. While Eli Lilly is the GLP-1 person today, Novo Nordisk was archetypal to marketplace with a GLP-1 drug. Eli Lilly's merchandise is much effectual and, thus, is selling better. Novo Nordisk is inactive innovating, and different competitors, similar Pfizer, are besides looking astatine the GLP-1 space. Eli Lilly could beryllium knocked from its throne conscionable arsenic easy arsenic Novo Nordisk was, successful a highly competitory sector.

That unsocial should person investors disquieted astir what Eli Lilly's concern volition look similar successful 10 years. But there's an adjacent much circumstantial menace to consider. Drugs are granted patent extortion for lone a constricted play of time. In a decade, Eli Lilly could beryllium staring down generic competition, which would usually trim the gross a branded cause generates. Even successful the best-case scenario, Eli Lilly's GLP-1 occurrence is time-limited.

Eli Lilly is alert of these issues and is spending contiguous to physique its cause pipeline for the future. However, investors buying Eli Lilly astatine its existent valuation request to see what the aboriginal mightiness look similar if, much apt when, the company's fortunes crook for the worse.